GlassScriptPhysician profile
Bryan L Wasson
NPI 1972537801
$136,196.12
in general payments reported to CMS, 2019-2025
75 companies · $11K in 2025
The $11K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $14K · 2021: $13K · 2022: $14K · 2023: $40K · 2024: $33K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Food and Beverage: $11K · Travel and Lodging: $5,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,900.00 |
| Food and Beverage | $11,241.40 |
| Travel and Lodging | $5,104.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100,000.44 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $12,377.54 | 2019-2023 | |
| Esperion Therapeutics, INC. | $6,557.10 | 2020-2025 | Nexletol, Nexlizet |
| Astrazeneca Pharmaceuticals LP | $2,030.09 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,982.82 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $1,659.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,476.22 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,272.34 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $1,035.41 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $850.81 | 2023-2025 | |
| Glaxosmithkline, LLC. | $778.01 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Radius Health, INC. | $508.31 | 2019-2025 | Tymlos |
| Dexcom, INC. | $422.34 | 2022-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Novartis Pharmaceuticals Corporation | $416.65 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $292.60 | 2019-2024 | Trintellix |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Wasson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.